Optimization of Tetrandrine Treatment in Rat Hepatic Fibrosis Model

Qin Pan,Ding-Guo Li,Han-Ming Lu,Qin-Fang Xu
2006-01-01
Abstract:Objective To optimize the therapeutic dosage of tetrandrine (Tet) in rat hepatic fibrosis model. Methods 50 Wistar rats were divided into 5 groups at random including normal control, model control, Tettreated model groups of 10mg•kg^(-1)•d^(-1), 5mg•kg^(-1)•d^(-1) and 2.5mg•kg^(-1)•d^(-1) (n=10 in each group). All rats, except for the normal controls, were injected with axenic porcine serum (0.5ml each time, twice a week) intraperitoneally for 8 weeks to establish hepatic fibrosis. After the 8th week, rats of Tet-treated model groups were given by gavage once a day with different doses of Tet for another 8 weeks. Then the liver function, serum levels of hyaluronic acid (HA), laminin (LM), and procollagen type Ⅲ (PCⅢ) were tested. Collagen type Ⅰ and Ⅲ, pathological changes in liver tissue were also assessed. Results Most indices of liver function including alanine minotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), albumin/globulin ratio (A/G) and alkaline phosphatase (ALP) improved significantly in Tet-treated groups with the exception of γ-glutamyl transpeptidase (γ-GT) and total bilirubin (TBIL). Secondly, markedly lowered levels of HA, IM and collagen type Ⅰ, Ⅲ were also detected by radioimmunology and immunohistochemistry in the 5mg•kg^(1-)•d^(-1) Tet-treated model group. Moreover, pathological findings confirmed the statistically signficant improvement in hepatofibrotic degree resulted from the treatment of 5mg•kg^(1-)•d^(-1) rather than other doses of Tet. Conclusion For experimental Wistar rats, Tet exhibited an anti-hepatofibrotic action in doses within the range of 2.5mg•kg^(1-)•d^(-1) to 10mg•kg^(1-)•d^(-1), and 5mg•kg^(1-)•d^(-1) may be the optimum one among all doses.
What problem does this paper attempt to address?